News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

TissueGene, Inc. Recognized During Maryland Commerce, State Departments' Week-Long Trade Mission To South Korea



9/11/2017 11:36:48 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs

ROCKVILLE, Md., Sept. 11, 2017 /PRNewswire/ -- A trade and diplomatic mission to South Korea led by officials from the Maryland Department of Commerce and the Maryland Secretary of State's office concluded the evening of Friday, September 8, 2017, with a reception at the U.S. Ambassador to South Korea's residence in Seoul.

From left to right, pictured here: TissueGene President and CEO Woosok Lee; First Lady Yumi Hogan; TEDCO Vice President for University Partnerships and Maryland Stem Cell Research Fund Executive Director Dan Gincel, Ph.D.; and Maryland Deputy Secretary of Commerce Ben Wu

The reception featured a check presentation by First Lady Yumi Hogan and Maryland Deputy Secretary of Commerce Ben Wu to TissueGene, Inc., a Rockville-based advanced cell therapies company that has developed a first-in-class cell and gene therapy targeting osteoarthritis (OA) of the knee. The $750,000 grant from Maryland's Stem Cell Research Fund, administered by TEDCO, was announced earlier this year and will help the company to successfully conduct Phase III clinical trials in the United States for its product Invossa, a first-in-class cell and gene therapy targeting OA of the knee through a single intra-articular injection. TissueGene has designed its Phase III program to seek a disease-modifying osteoarthritis drug (DMOAD) designation for Invossa from the U.S. Food and Drug Administration (FDA)potentially making Invossa the first therapy to receive a DMOAD label. In July 2017, Kolon Life Science, Inc., TissueGene's exclusive licensee for Asia, received South Korean MFDS marketing approval for Invossa-K Inj.

About TissueGene, Inc.
TissueGene, Inc., is an advanced cell therapies company that has developed a first-in-class cell and gene therapy targeting OA of the knee. TissueGene's lead product, Invossa, is an allogeneic cell and gene therapy. The Company is preparing for Phase III clinical trials in the U.S. under a Special Protocol Assessment (SPA) agreement reached with the U.S. Food and Drug Administration (FDA). Information about the trials can be found at the National Institutes of Health registry, www.clinicaltrials.gov.  For additional information about TissueGene, Inc., please visit www.tissuegene.com.

 

TissueGene, Inc. Logo (PRNewsFoto/TissueGene, Inc.)

View original content with multimedia:http://www.prnewswire.com/news-releases/tissuegene-recognized-during-maryland-commerce-state-departments-week-long-trade-mission-to-south-korea-300517217.html

SOURCE TissueGene, Inc.


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES